Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor–Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype—ACOSOG Z1031

PURPOSE: Preoperative aromatase inhibitor (AI) treatment promotes breast-conserving surgery (BCS) for estrogen receptor (ER) –positive breast cancer. To study this treatment option, responses to three AIs were compared in a randomized phase II neoadjuvant trial designed to select agents for phase II...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς: Ellis, Matthew J., Suman, Vera J., Hoog, Jeremy, Lin, Li, Snider, Jacqueline, Prat, Aleix, Parker, Joel S., Luo, Jingqin, DeSchryver, Katherine, Allred, D. Craig, Esserman, Laura J., Unzeitig, Gary W., Margenthaler, Julie, Babiera, Gildy V., Marcom, P. Kelly, Guenther, Joseph M., Watson, Mark A., Leitch, Marilyn, Hunt, Kelly, Olson, John A.
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: American Society of Clinical Oncology 2011
Θέματα:
Original Reports
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3107749/
https://ncbi.nlm.nih.gov/pubmed/21555689
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2010.31.6950
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια